Cell and gene therapy for HIV cure webinar series now open for registration

The Delaney AIDS Research Enterprise (DARE), one of the NIH’s Martin Delaney Collaboratories for HIV Cure Research, in conjunction with the DARE Community Advisory Board (CAB), will present a free eight-part webinar series on the latest developments in HIV cure-related cell and gene therapy beginning June 21, 2022.

The use of cell and gene therapy against HIV is a promising new cure-related strategy, with the potential to target the virus with a limited number of doses. The webinar series will allow participants to take part in discussions with experts in the field, learn about their cutting edge work, and hear about potential side effects that people should be aware of before they consider enrolling in these clinical trials.

The series begins in June 2022 and ends in February 2023. Each monthly session will last an hour, with question-and-answer periods that include DARE CAB members to ensure the community perspective is covered.

Webinar topics and speakers:

  • June 21, 2022: The Basics: Jennifer Adair, PhD, Fred Hutch, Global Gene Therapy Initiative; Michael Louella, DARE CAB Co-Chair
  • July 19, 2022: Designing T Cells for HIV Cure Studies: James Riley, PhD, University of PA
  • August 16, 2022: Cutting Out HIV with CRISPR: Kamel Khalili, PhD, Temple University, CRIPSR for Cure; Tricia Burdo, PhD, Temple University, CRIPSR for Cure
  • September 20, 2022: Silencing HIV: Priti Kumar, PhD, Yale University, HOPE
  • October 18, 2022: Gene Therapy in Germany: Prof. Dr. Joachim Hauber, PROVIREX Genome Editing Therapies GmbH, Hamburg, DE
  • November 15, 2022: Duo CAR T cells: Kim Anthony-Gonda, PhD, MB, ASCP, Caring Cross
  • January 17, 2023: Engineering B Cells: Paula Cannon, PhD, UCS, RID
  • February, 28, 2023: Gene Therapy in Africa: Boro Dropulic, PhD, MBA, Caring Cross

Registration is required. To register, click herehttps://bit.ly/3kapavg.

For more information, contact Lynda Dee.